title: An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF kappa B in human osteosarcoma.
abstract: BACKGROUND
  Dominant negative inhibition of nuclear factor kappa B (NF kappa B) signalling activity in a human osteosarcoma cell line (Saos2) results in malignant reversion and the induction of the osteoblast differentiating transcription factor, Runx2/Cbfa1. This observation suggests that there is an inverse relation between a transcription factor associated with malignant progression and chemoresistance (NF kappa B) and an osteoblast differentiating transcription factor (Runx2/Cbfa1).
  
  
  OBJECTIVE
  To assess and correlate Runx2/Cbfa1 and NF kappa B (p65) immunoreactivity in human osteosarcoma.
  
  
  METHODS
  Runx2/Cbfa1 and NFkappaB (p65) immunoreactivity was assessed on 11 paraffin wax embedded archival specimens of human primary osteosarcoma by standard immunohistochemical methods and scored on a scale of 0-3. A Pearson correlation analysis between Runx2/Cbfa1 and NF kappa B (p65) scores was established.
  
  
  RESULTS
  Runx2/Cbfa1 was expressed constitutively in all pathology specimens of human osteosarcoma. Of note, a chondroblastic osteosarcoma showed the highest Runx2/Cbfa1 immunoreactivity. A Pearson correlation did not support an inverse correlation between Runx2/Cbfa1 and NF kappa B (p65) scores (r = 0.57) in human osteosarcoma.
  
  
  CONCLUSIONS
  Runx2/Cbfa1 immunoreactivity does not inversely correlate with NF kappa B immunoreactivity, and thus cannot serve as an indirect measure of NF kappa B activity or an independent predictive or prognostic indicator.
authors.affiliation: The James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue Box 665, Rochester, NY 14642, USA. v_andela@yahoo.com
authors.forename: V B
authors.initials: VB
authors.lastname: Andela
authors.forename: F
authors.initials: F
authors.lastname: Siddiqui
authors.forename: A
authors.initials: A
authors.lastname: Groman
authors.forename: R N
authors.initials: RN
authors.lastname: Rosier
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000473:pathology; D050659:Core Binding Factor Alpha 1 Subunit; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D016328:NF-kappa B / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism; D012516:Osteosarcoma / Q000378:metabolism* / Q000473:pathology; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D050659:Core Binding Factor Alpha 1 Subunit; D004268:DNA-Binding Proteins; D016328:NF-kappa B; D009363:Neoplasm Proteins; C493709:RUNX2 protein, human; D050656:Transcription Factor AP-2; D014157:Transcription Factors
references.citation: Cancer Res. 2000 Dec 1;60(23):6557-62
references.pmid: 11118032
references.citation: Mol Cell. 2001 Aug;8(2):303-16
references.pmid: 11545733
references.citation: Nature. 2001 Nov 1;414(6859):105-11
references.pmid: 11689955
references.citation: Dev Biol. 2002 May 1;245(1):95-108
references.pmid: 11969258
references.citation: Biochem Biophys Res Commun. 2002 Sep 20;297(2):237-41
references.pmid: 12237108
references.citation: Nat Med. 1999 Apr;5(4):412-7
references.pmid: 10202930
references.citation: Curr Opin Genet Dev. 2004 Feb;14(1):43-7
references.pmid: 15108804
references.citation: J Clin Oncol. 1994 Feb;12(2):423-31
references.pmid: 8113851
references.citation: Cell. 1997 May 30;89(5):747-54
references.pmid: 9182762
references.citation: J Surg Oncol. 1997 Jun;65(2):95-105
references.pmid: 9209520
references.citation: Cancer Res. 2003 Sep 1;63(17):5357-62
references.pmid: 14500368